BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mulloy B, Hogwood J, Gray E, Lever R, Page CP. Pharmacology of Heparin and Related Drugs. Pharmacol Rev 2016;68:76-141. [PMID: 26672027 DOI: 10.1124/pr.115.011247] [Cited by in Crossref: 149] [Cited by in F6Publishing: 125] [Article Influence: 24.8] [Reference Citation Analysis]
Number Citing Articles
1 Spadarella G, Di Minno A, Donati MB, Mormile M, Ventre I, Di Minno G. From unfractionated heparin to pentasaccharide: Paradigm of rigorous science growing in the understanding of the in vivo thrombin generation. Blood Reviews 2020;39:100613. [DOI: 10.1016/j.blre.2019.100613] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
2 Miura T, Kawano M, Takahashi K, Yuasa N, Habu M, Kimura F, Imamura T, Nakayama F. High-Sulfated Hyaluronic Acid Ameliorates Radiation-Induced Intestinal Damage Without Blood Anticoagulation. Advances in Radiation Oncology 2022;7:100900. [DOI: 10.1016/j.adro.2022.100900] [Reference Citation Analysis]
3 Vasconcelos AA, Sucupira ID, Guedes AL, Queiroz IN, Frattani FS, Fonseca RJ, Pomin VH. Anticoagulant and Antithrombotic Properties of Three Structurally Correlated Sea Urchin Sulfated Glycans and Their Low-Molecular-Weight Derivatives. Mar Drugs 2018;16:E304. [PMID: 30200211 DOI: 10.3390/md16090304] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
4 Mulloy B. The non-anticoagulant promise of heparin and its mimetics. Curr Opin Pharmacol 2019;46:50-4. [PMID: 31009826 DOI: 10.1016/j.coph.2019.03.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
5 Patriota YBG, Chaves LL, Gocke EH, Severino P, Soares MFR, Soares-sobrinho JL, Souto EB. Applied Nanotechnologies in Anticoagulant Therapy: From Anticoagulants to Coagulation Test Performance of Drug Delivery Systems. Applied Nano 2021;2:98-117. [DOI: 10.3390/applnano2020009] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Lisztes E, Mező E, Demeter F, Horváth L, Bősze S, István Tóth B, Borbás A, Herczeg M. Synthesis and Cell Growth Inhibitory Activity of Six Non-glycosaminoglycan-Type Heparin-Analogue Trisaccharides. ChemMedChem 2021;16:1467-76. [PMID: 33433040 DOI: 10.1002/cmdc.202000917] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Schrezenmeier EV, Burmester GR, Eckardt K, Dörner T. Role for antimalarials in the management of COVID-19. Current Opinion in Rheumatology 2020;32:449-57. [DOI: 10.1097/bor.0000000000000731] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
8 Zhao C, Wu Z, Chu H, Wang T, Qiu S, Zhou J, Zhu Q, Liu X, Quan D, Bai Y. Thiol-Rich Multifunctional Macromolecular Crosslinker for Gelatin-Norbornene-Based Bioprinting. Biomacromolecules 2021;22:2729-39. [PMID: 34057830 DOI: 10.1021/acs.biomac.1c00421] [Reference Citation Analysis]
9 Li Q, Niu Y, Xing P, Wang C. Bioactive polysaccharides from natural resources including Chinese medicinal herbs on tissue repair. Chin Med 2018;13:7. [PMID: 29445417 DOI: 10.1186/s13020-018-0166-0] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 9.3] [Reference Citation Analysis]
10 Bachler M, Hell T, Bösch J, Treml B, Schenk B, Treichl B, Friesenecker B, Lorenz I, Stengg D, Hruby S, Wallner B, Oswald E, Ströhle M, Niederwanger C, Irsara C, Fries D. A Prospective Pilot Trial to Assess the Efficacy of Argatroban (Argatra®) in Critically Ill Patients with Heparin Resistance. J Clin Med 2020;9:E963. [PMID: 32244368 DOI: 10.3390/jcm9040963] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
11 Zyryanov SK, Ushkalova EA. [Enoxaparin is a low-molecular-weight heparin with a complex chemical structure and various non-anticoagulant properties]. Ter Arkh 2016;88:109-15. [PMID: 28635885 DOI: 10.17116/terarkh20168812109-115] [Reference Citation Analysis]
12 Nagarajan B, Desai U. Aqueous Molecular Dynamics for Understanding Glycosaminoglycan Recognition by Proteins. Methods Mol Biol 2022;2303:49-62. [PMID: 34626369 DOI: 10.1007/978-1-0716-1398-6_5] [Reference Citation Analysis]
13 Zhang S, Li ZT, Liu M, Wang JR, Xu MQ, Li ZY, Duan XC, Hao YL, Zheng XC, Li H, Feng ZH, Zhang X. Anti-tumour activity of low molecular weight heparin doxorubicin nanoparticles for histone H1 high-expressive prostate cancer PC-3M cells. J Control Release 2019;295:102-17. [PMID: 30582952 DOI: 10.1016/j.jconrel.2018.12.034] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
14 dos Santos-fidencio GC, Gonçalves AG, Noseda MD, Duarte MER, Ducatti DR. Effects of carboxyl group on the anticoagulant activity of oxidized carrageenans. Carbohydrate Polymers 2019;214:286-93. [DOI: 10.1016/j.carbpol.2019.03.057] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
15 Qiu XL, Fan ZR, Liu YY, Wang DF, Wang SX, Li CX. Preparation and Evaluation of a Self-Nanoemulsifying Drug Delivery System Loaded with Heparin Phospholipid Complex. Int J Mol Sci 2021;22:4077. [PMID: 33920853 DOI: 10.3390/ijms22084077] [Reference Citation Analysis]
16 Meloni MM, Barton S, Kaski JC, Song W, He T. An improved synthesis of a cyclopropene-based molecule for the fabrication of bioengineered tissues via copper-free click chemistry. J Appl Biomater Funct Mater 2019;17:2280800019844746. [PMID: 31223071 DOI: 10.1177/2280800019844746] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
17 Dou H, Song A, Jia S, Zhang L. Heparinoids Danaparoid and Sulodexide as clinically used drugs. Glycans and Glycosaminoglycans as Clinical Biomarkers and Therapeutics - Part B. Elsevier; 2019. pp. 55-74. [DOI: 10.1016/bs.pmbts.2019.02.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
18 Pomin VH. ¹H and (15)N NMR Analyses on Heparin, Heparan Sulfates and Related Monosaccharides Concerning the Chemical Exchange Regime of the N-Sulfo-Glucosamine Sulfamate Proton. Pharmaceuticals (Basel) 2016;9:E58. [PMID: 27618066 DOI: 10.3390/ph9030058] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
19 Jeske W, Kouta A, Duff R, Rangnekar V, Niverthi M, Hoppensteadt D, Fareed J, Yao Y. Comparative Pharmacokinetic Profile of 3 Batches of Ovine Low-Molecular-Weight Heparin and 1 Batch of Branded Enoxaparin. Clin Appl Thromb Hemost 2018;24:150S-6S. [PMID: 30198315 DOI: 10.1177/1076029618798956] [Reference Citation Analysis]
20 Rudd TR, Mauri L, Marinozzi M, Stancanelli E, Yates EA, Naggi A, Guerrini M. Multivariate analysis applied to complex biological medicines. Faraday Discuss 2019;218:303-16. [PMID: 31123736 DOI: 10.1039/c9fd00009g] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
21 Marques C, Reis CA, Vivès RR, Magalhães A. Heparan Sulfate Biosynthesis and Sulfation Profiles as Modulators of Cancer Signalling and Progression. Front Oncol 2021;11:778752. [PMID: 34858858 DOI: 10.3389/fonc.2021.778752] [Reference Citation Analysis]
22 Nurcombe V, Ling L, Hondermarck H, Cool SM, Smith RAA. Bringing Heparan Sulfate Glycomics Together with Proteomics for the Design of Novel Therapeutics: A Historical Perspective. Proteomics 2019;19:e1800466. [PMID: 31197945 DOI: 10.1002/pmic.201800466] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
23 Barbosa LC, Gonçalves TL, de Araujo LP, Rosario LVO, Ferrer VP. Endothelial cells and SARS-CoV-2: An intimate relationship. Vascul Pharmacol 2021;137:106829. [PMID: 33422689 DOI: 10.1016/j.vph.2021.106829] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
24 Wang X, Xie Y, Jiang N, Wang J, Liang H, Liu D, Yang N, Sang X, Feng Y, Chen R, Chen Q. Enhanced Antimalarial Efficacy Obtained by Targeted Delivery of Artemisinin in Heparin-Coated Magnetic Hollow Mesoporous Nanoparticles. ACS Appl Mater Interfaces 2021;13:287-97. [PMID: 33356111 DOI: 10.1021/acsami.0c20070] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Hogwood J, Pitchford S, Mulloy B, Page C, Gray E. Heparin and non-anticoagulant heparin attenuate histone-induced inflammatory responses in whole blood. PLoS One 2020;15:e0233644. [PMID: 32469940 DOI: 10.1371/journal.pone.0233644] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
26 Tree JA, Turnbull JE, Buttigieg KR, Elmore MJ, Coombes N, Hogwood J, Mycroft-West CJ, Lima MA, Skidmore MA, Karlsson R, Chen YH, Yang Z, Spalluto CM, Staples KJ, Yates EA, Gray E, Singh D, Wilkinson T, Page CP, Carroll MW. Unfractionated heparin inhibits live wild type SARS-CoV-2 cell infectivity at therapeutically relevant concentrations. Br J Pharmacol 2021;178:626-35. [PMID: 33125711 DOI: 10.1111/bph.15304] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 11.5] [Reference Citation Analysis]
27 Faour WH, Choaib A, Issa E, Choueiry FE, Shbaklo K, Alhajj M, Sawaya RT, Harhous Z, Alefishat E, Nader M. Mechanisms of COVID-19-induced kidney injury and current pharmacotherapies. Inflamm Res 2021. [PMID: 34802072 DOI: 10.1007/s00011-021-01520-8] [Reference Citation Analysis]
28 Ustyuzhanina NE, Bilan MI, Nifantiev NE, Usov AI. New insight on the structural diversity of holothurian fucosylated chondroitin sulfates. Pure and Applied Chemistry 2019;91:1065-71. [DOI: 10.1515/pac-2018-1211] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 3.7] [Reference Citation Analysis]
29 Achazi K, Haag R, Ballauff M, Dernedde J, Kizhakkedathu JN, Maysinger D, Multhaup G. Wechselwirkung von Polyelektrolyt‐Architekturen mit Proteinen und Biosystemen. Angew Chem 2021;133:3926-50. [DOI: 10.1002/ange.202006457] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Gritsch L, Conoscenti G, La Carrubba V, Nooeaid P, Boccaccini AR. Polylactide-based materials science strategies to improve tissue-material interface without the use of growth factors or other biological molecules. Materials Science and Engineering: C 2019;94:1083-101. [DOI: 10.1016/j.msec.2018.09.038] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 5.3] [Reference Citation Analysis]
31 Rezagholizadeh A, Adib ZK, Entezari-Maleki T. Evaluation of the activated partial thromboplastin time and its influential factors in ischemic heart disease patients under heparin treatment. Blood Coagul Fibrinolysis 2021;32:496-503. [PMID: 34650022 DOI: 10.1097/MBC.0000000000001088] [Reference Citation Analysis]
32 Xu X, Huang X, Zhang Y, Shen S, Feng Z, Dong H, Zhang C, Mo R. Self-regulated hirudin delivery for anticoagulant therapy. Sci Adv 2020;6:eabc0382. [PMID: 33036973 DOI: 10.1126/sciadv.abc0382] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
33 Cleary SJ, Pitchford SC, Amison RT, Carrington R, Robaina Cabrera CL, Magnen M, Looney MR, Gray E, Page CP. Animal models of mechanisms of SARS-CoV-2 infection and COVID-19 pathology. Br J Pharmacol 2020;177:4851-65. [PMID: 32462701 DOI: 10.1111/bph.15143] [Cited by in Crossref: 58] [Cited by in F6Publishing: 56] [Article Influence: 29.0] [Reference Citation Analysis]
34 de Jesus-Silva SG, de Moraes Silva MA, Carbonel AAF, Grillo Filho GFR, Grigório TS, Simões MJ, Cardoso RS, Fagundes DJ. Heparin Attenuates Visceral Apoptosis in a Swine Model of Hemorrhagic Shock and Reperfusion Injury. Ann Vasc Surg 2020;67:449-60. [PMID: 32179141 DOI: 10.1016/j.avsg.2020.01.106] [Reference Citation Analysis]
35 Terrigno VR, Ricketti DA, Patel P, Roy S. Recurrent chronic thromboembolic disease despite optimal anticoagulation in setting of recent COVID-19 infection. BMJ Case Rep 2021;14:e238733. [PMID: 33509878 DOI: 10.1136/bcr-2020-238733] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Coron AE, Kjesbu JS, Kjærnsmo F, Oberholzer J, Rokstad AMA, Strand BL. Pericapsular fibrotic overgrowth mitigated in immunocompetent mice through microbead formulations based on sulfated or intermediate G alginates. Acta Biomater 2021:S1742-7061(21)00662-0. [PMID: 34634509 DOI: 10.1016/j.actbio.2021.10.004] [Reference Citation Analysis]
37 Li B, Zhao H, Yu M. Techniques for Detection of Clinical Used Heparins. Int J Anal Chem 2021;2021:5543460. [PMID: 34040644 DOI: 10.1155/2021/5543460] [Reference Citation Analysis]
38 Várnai B, Grabarics M, Szakács Z, Pagel K, Malanga M, Sohajda T, Béni S. Structural characterization of fondaparinux interaction with per-6-amino-beta-cyclodextrin: An NMR and MS study. J Pharm Biomed Anal 2021;197:113947. [PMID: 33601159 DOI: 10.1016/j.jpba.2021.113947] [Reference Citation Analysis]
39 Lanzi C, Cassinelli G. Heparan Sulfate Mimetics in Cancer Therapy: The Challenge to Define Structural Determinants and the Relevance of Targets for Optimal Activity. Molecules 2018;23:E2915. [PMID: 30413079 DOI: 10.3390/molecules23112915] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 6.5] [Reference Citation Analysis]
40 Zeng Y, Xiang Y, Sheng R, Tomás H, Rodrigues J, Gu Z, Zhang H, Gong Q, Luo K. Polysaccharide-based nanomedicines for cancer immunotherapy: A review. Bioactive Materials 2021;6:3358-82. [DOI: 10.1016/j.bioactmat.2021.03.008] [Reference Citation Analysis]
41 Kole MJ, Wessell AP, Ugiliweneza B, Cannarsa GJ, Fortuny E, Stokum JA, Shea P, Chryssikos T, Khattar NK, Crabill GA, Schreibman DL, Badjatia N, Gandhi D, Aldrich EF, James RF, Simard JM. Low-Dose Intravenous Heparin Infusion After Aneurysmal Subarachnoid Hemorrhage is Associated With Decreased Risk of Delayed Neurological Deficit and Cerebral Infarction. Neurosurgery 2021;88:523-30. [PMID: 33269390 DOI: 10.1093/neuros/nyaa473] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
42 Tu B, Wang H, An X, Qu J, Li Q, Gao Y, Shi M, Qiu H, Huang Y. Inhaled heparin polysaccharide nanodecoy against SARS-CoV-2 and variants. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.01.019] [Reference Citation Analysis]
43 Gao Y, Zhang L, Jiao W. Marine glycan-derived therapeutics in China. Glycans and Glycosaminoglycans as Clinical Biomarkers and Therapeutics - Part B. Elsevier; 2019. pp. 113-34. [DOI: 10.1016/bs.pmbts.2019.02.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
44 Teixeira SPB, Domingues RMA, Shevchuk M, Gomes ME, Peppas NA, Reis RL. Biomaterials for Sequestration of Growth Factors and Modulation of Cell Behavior. Adv Funct Mater 2020;30:1909011. [DOI: 10.1002/adfm.201909011] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 8.5] [Reference Citation Analysis]
45 Lan X, Huang Z, Tan Z, Huang Z, Wang D, Huang Y. Nebulized heparin for inhalation injury in burn patients: a systematic review and meta-analysis. Burns Trauma 2020;8:tkaa015. [PMID: 32523966 DOI: 10.1093/burnst/tkaa015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
46 Zhu Y, Zhang F, Linhardt RJ. Heparin Contamination and Issues Related to Raw Materials and Controls. In: Sasisekharan R, Lee SL, Rosenberg A, Walker LA, editors. The Science and Regulations of Naturally Derived Complex Drugs. Cham: Springer International Publishing; 2019. pp. 191-206. [DOI: 10.1007/978-3-030-11751-1_11] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Mulloy B, Lever R, Page CP. Mast cell glycosaminoglycans. Glycoconj J 2017;34:351-61. [PMID: 27900574 DOI: 10.1007/s10719-016-9749-0] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 5.5] [Reference Citation Analysis]
48 Hamza MS, Mousa SA. Cancer-Associated Thrombosis: Risk Factors, Molecular Mechanisms, Future Management. Clin Appl Thromb Hemost 2020;26:1076029620954282. [PMID: 32877229 DOI: 10.1177/1076029620954282] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
49 Ye M, Yu J, Shi X, Zhu J, Gao X, Liu W. Polysaccharides catabolism by the human gut bacterium -Bacteroides thetaiotaomicron: advances and perspectives. Crit Rev Food Sci Nutr 2020;:1-20. [PMID: 32779480 DOI: 10.1080/10408398.2020.1803198] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
50 Wu J, Long Y, Li M, He Q. Emerging nanomedicine-based therapeutics for hematogenous metastatic cascade inhibition: Interfering with the crosstalk between "seed and soil". Acta Pharm Sin B 2021;11:2286-305. [PMID: 34522588 DOI: 10.1016/j.apsb.2020.11.024] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Lobastov K, Dementieva G, Soshitova N, Bargandzhiya A, Barinov V, Laberko L, Rodoman G. Utilization of the Caprini score in conjunction with thrombodynamic testing reduces the number of unpredicted postoperative venous thromboembolism events in patients with colorectal cancer. J Vasc Surg Venous Lymphat Disord 2020;8:31-41. [PMID: 31495765 DOI: 10.1016/j.jvsv.2019.06.015] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
52 Ji Y, Wang Y, Zeng W, Mei X, Du S, Yan Y, Hao J, Zhang Z, Lu Y, Zhang C, Ge J, Xing XH. A heparin derivatives library constructed by chemical modification and enzymatic depolymerization for exploitation of non-anticoagulant functions. Carbohydr Polym 2020;249:116824. [PMID: 32933671 DOI: 10.1016/j.carbpol.2020.116824] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
53 Di Micco P, Imbalzano E, Russo V, Attena E, Mandaliti V, Orlando L, Lombardi M, Di Micco G, Camporese G, Annunziata S, Piccinocchi G, Pacelli W, Del Guercio M. Heparin and SARS-CoV-2: Multiple Pathophysiological Links. Viruses 2021;13:2486. [PMID: 34960754 DOI: 10.3390/v13122486] [Reference Citation Analysis]
54 Ray B, Ali I, Jana S, Mukherjee S, Pal S, Ray S, Schütz M, Marschall M. Antiviral Strategies Using Natural Source-Derived Sulfated Polysaccharides in the Light of the COVID-19 Pandemic and Major Human Pathogenic Viruses. Viruses 2021;14:35. [PMID: 35062238 DOI: 10.3390/v14010035] [Reference Citation Analysis]
55 Ennemoser M, Rieger J, Muttenthaler E, Gerlza T, Zatloukal K, Kungl AJ. Enoxaparin and Pentosan Polysulfate Bind to the SARS-CoV-2 Spike Protein and Human ACE2 Receptor, Inhibiting Vero Cell Infection. Biomedicines 2022;10:49. [DOI: 10.3390/biomedicines10010049] [Reference Citation Analysis]
56 Wei J, Wu J, Tang Y, Ridgeway ME, Park MA, Costello CE, Zaia J, Lin C. Characterization and Quantification of Highly Sulfated Glycosaminoglycan Isomers by Gated-Trapped Ion Mobility Spectrometry Negative Electron Transfer Dissociation MS/MS. Anal Chem 2019;91:2994-3001. [PMID: 30649866 DOI: 10.1021/acs.analchem.8b05283] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 10.0] [Reference Citation Analysis]
57 Gerotziafas GT, Catalano M, Colgan MP, Pecsvarady Z, Wautrecht JC, Fazeli B, Olinic DM, Farkas K, Elalamy I, Falanga A, Fareed J, Papageorgiou C, Arellano RS, Agathagelou P, Antic D, Auad L, Banfic L, Bartolomew JR, Benczur B, Bernardo MB, Boccardo F, Cifkova R, Cosmi B, De Marchi S, Dimakakos E, Dimopoulos MA, Dimitrov G, Durand-Zaleski I, Edmonds M, El Nazar EA, Erer D, Esponda OL, Gresele P, Gschwandtner M, Gu Y, Heinzmann M, Hamburg NM, Hamadé A, Jatoi NA, Karahan O, Karetova D, Karplus T, Klein-Weigel P, Kolossvary E, Kozak M, Lefkou E, Lessiani G, Liew A, Marcoccia A, Marshang P, Marakomichelakis G, Matuska J, Moraglia L, Pillon S, Poredos P, Prior M, Salvador DRK, Schlager O, Schernthaner G, Sieron A, Spaak J, Spyropoulos A, Sprynger M, Suput D, Stanek A, Stvrtinova V, Szuba A, Tafur A, Vandreden P, Vardas PE, Vasic D, Vikkula M, Wennberg P, Zhai Z; Scientific Reviewer Committee. Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine. Thromb Haemost 2020;120:1597-628. [PMID: 32920811 DOI: 10.1055/s-0040-1715798] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 21.0] [Reference Citation Analysis]
58 Xu M, Hu K, Liu Y, Huang Y, Liu S, Chen Y, Wang D, Zhou S, Zhang Q, Mei N, Lu H, Li F, Gao X, Chen J. Systemic metastasis-targeted nanotherapeutic reinforces tumor surgical resection and chemotherapy. Nat Commun 2021;12:3187. [PMID: 34045459 DOI: 10.1038/s41467-021-23466-5] [Reference Citation Analysis]
59 Brown MA, Najam F, Pocock ES, Munoz PF, Farrar KA, Yamane DP. A comparison of bivalirudin and heparin for patients on extracorporeal membrane oxygenation. Thromb Res 2020;190:76-8. [PMID: 32315870 DOI: 10.1016/j.thromres.2020.04.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
60 Devlin A, Mycroft-West C, Procter P, Cooper L, Guimond S, Lima M, Yates E, Skidmore M. Tools for the Quality Control of Pharmaceutical Heparin. Medicina (Kaunas) 2019;55:E636. [PMID: 31557911 DOI: 10.3390/medicina55100636] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
61 Mycroft-West CJ, Devlin AJ, Cooper LC, Procter P, Miller GJ, Fernig DG, Guerrini M, Guimond SE, Lima MA, Yates EA, Skidmore MA. Inhibition of BACE1, the β-secretase implicated in Alzheimer's disease, by a chondroitin sulfate extract from Sardina pilchardus. Neural Regen Res 2020;15:1546-53. [PMID: 31997821 DOI: 10.4103/1673-5374.274341] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
62 Bertanha M, Rodrigues LDS, Mellucci Filho PL, Moroz A, Pardini MIMC, Sobreira ML, Durigon EL, Machado RRG, Grotto RMT, Lima MA, Nader HB, Moraes ML, Barbosa AN, Medolago NB, Cardoso FF, Magro AJ, Carvalho CRG, Moraes LN, Alvarado RC, Nunes HC, Campos GC, Grillo VTRDS, Sertorio ND, Fortaleza CMCB. Nebulized enriched heparin to treat no critical patients with Sars-Cov-2: Triple-blind clinical trial. Medicine (Baltimore) 2021;100:e28288. [PMID: 34941114 DOI: 10.1097/MD.0000000000028288] [Reference Citation Analysis]
63 Pomin VH, Mulloy B. Glycosaminoglycans and Proteoglycans. Pharmaceuticals (Basel) 2018;11:E27. [PMID: 29495527 DOI: 10.3390/ph11010027] [Cited by in Crossref: 72] [Cited by in F6Publishing: 63] [Article Influence: 18.0] [Reference Citation Analysis]
64 Yi L, Zhang Q, Meng Y, Hao J, Xie B, Gan H, Li D, Dong K, Zhang Z. Qualitative and quantitative analysis of 2, 5-anhydro-d-mannitol in low molecular weight heparins with high performance anion exchange chromatography hyphenated quadrupole time of flight mass spectrometry. Journal of Chromatography A 2018;1569:160-7. [DOI: 10.1016/j.chroma.2018.07.058] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
65 Telen MJ, Batchvarova M, Shan S, Bovee-Geurts PH, Zennadi R, Leitgeb A, Brock R, Lindgren M. Sevuparin binds to multiple adhesive ligands and reduces sickle red blood cell-induced vaso-occlusion. Br J Haematol 2016;175:935-48. [PMID: 27549988 DOI: 10.1111/bjh.14303] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 5.2] [Reference Citation Analysis]
66 Zeng Y, Xiang Y, Sheng R, Tomás H, Rodrigues J, Gu Z, Zhang H, Gong Q, Luo K. Polysaccharide-based nanomedicines for cancer immunotherapy: A review. Bioact Mater 2021;6:3358-82. [PMID: 33817416 DOI: 10.1016/j.bioactmat.2021.03.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
67 Xu L, Gao N, Xiao C, Lin L, Purcell SW, Wu M, Zhao J. Modulating the degree of fucosylation of fucosylated chondroitin sulfate enhances heparin cofactor II-dependent thrombin inhibition. Eur J Med Chem 2018;154:133-43. [PMID: 29787913 DOI: 10.1016/j.ejmech.2018.05.024] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
68 Hao C, Xu H, Yu L, Zhang L. Heparin: An essential drug for modern medicine. Prog Mol Biol Transl Sci 2019;163:1-19. [PMID: 31030744 DOI: 10.1016/bs.pmbts.2019.02.002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 6.7] [Reference Citation Analysis]
69 Cavalcante MB, Cavalcante CTMB, Braga ACS, Andrade DA, Montenegro MA, Santos PAN, Motoyama PVP, Rocha MG, Dib LA, Araujo Júnior E. COVID-19 Treatment: Drug Safety Prior to Conception and During Pregnancy and Breastfeeding. Geburtshilfe Frauenheilkd 2021;81:46-60. [PMID: 33487665 DOI: 10.1055/a-1247-5271] [Reference Citation Analysis]
70 Tovar AM, Santos GR, Capillé NV, Piquet AA, Glauser BF, Pereira MS, Vilanova E, Mourão PA. Structural and haemostatic features of pharmaceutical heparins from different animal sources: challenges to define thresholds separating distinct drugs. Sci Rep 2016;6:35619. [PMID: 27752111 DOI: 10.1038/srep35619] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
71 Nagarajan B, Sankaranarayanan NV, Patel BB, Desai UR. A molecular dynamics-based algorithm for evaluating the glycosaminoglycan mimicking potential of synthetic, homogenous, sulfated small molecules. PLoS One 2017;12:e0171619. [PMID: 28182755 DOI: 10.1371/journal.pone.0171619] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
72 van der Meer JY, Kellenbach E, van den Bos LJ. From Farm to Pharma: An Overview of Industrial Heparin Manufacturing Methods. Molecules 2017;22:E1025. [PMID: 28635655 DOI: 10.3390/molecules22061025] [Cited by in Crossref: 39] [Cited by in F6Publishing: 29] [Article Influence: 7.8] [Reference Citation Analysis]
73 Sankaranarayanan NV, Nagarajan B, Desai UR. So you think computational approaches to understanding glycosaminoglycan-protein interactions are too dry and too rigid? Think again! Curr Opin Struct Biol 2018;50:91-100. [PMID: 29328962 DOI: 10.1016/j.sbi.2017.12.004] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 10.0] [Reference Citation Analysis]
74 Post R, Zijlstra IA, Berg RVD, Coert BA, Verbaan D, Vandertop WP. High-Dose Nadroparin Following Endovascular Aneurysm Treatment Benefits Outcome After Aneurysmal Subarachnoid Hemorrhage. Neurosurgery 2018;83:281-7. [DOI: 10.1093/neuros/nyx381] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
75 Yu Y, Chen Y, Mikael P, Zhang F, Stalcup AM, German R, Gould F, Ohlemacher J, Zhang H, Linhardt RJ. Surprising absence of heparin in the intestinal mucosa of baby pigs. Glycobiology 2017;27:57-63. [PMID: 27744271 DOI: 10.1093/glycob/cww104] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
76 Abraham M, Badhey A, Hu S, Kadakia S, Rasamny JK, Moscatello A, Ducic Y. Thromboprophylaxis in Head and Neck Microvascular Reconstruction. Craniomaxillofac Trauma Reconstr 2018;11:85-95. [PMID: 29892322 DOI: 10.1055/s-0037-1607068] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
77 Qiu Q, Li GJ, Tang L, Guo Y, Wen LZ, Wang B, Chen DF, Liu KJ. The efficacy of low molecular weight heparin in severe acute pancreatitis: A systematic review and meta‐analysis of randomized controlled trials. J Dig Dis 2019;20:512-22. [DOI: 10.1111/1751-2980.12815] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
78 Deng Z, Qin J, Sun H, Xv F, Ma Y. Effectiveness of Impregnated Central Venous Catheters on Catheter-Related Bloodstream Infection in Pediatrics. Front Pediatr 2022;10:795019. [DOI: 10.3389/fped.2022.795019] [Reference Citation Analysis]
79 Wang K, Liu M, Mo R. Polysaccharide-Based Biomaterials for Protein Delivery. Medicine in Drug Discovery 2020;7:100031. [DOI: 10.1016/j.medidd.2020.100031] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
80 Chagas AP, Peixoto BP, Costa BBD, Moreira TA, Cinelli LP, da Silva LL, Miranda-Alves L, Berto-Junior C. Effects of bisphenol A and S on blood coagulation: in vivo, in vitro and in silico approaches in toxicodynamic. Toxicol Mech Methods 2021;31:90-9. [PMID: 33054482 DOI: 10.1080/15376516.2020.1836102] [Reference Citation Analysis]
81 Urbanek T, Labropoulos N. Can we predict and prevent the postthrombotic syndrome? Vasa 2021;50:11-21. [PMID: 33393384 DOI: 10.1024/0301-1526/a000932] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
82 Ding L, Hao J, Luo X, Zhu W, Wu Z, Qian Y, Hu F, Liu T, Ruan X, Li S, Li J, Chen Z. The Kv1.3 channel-inhibitory toxin BF9 also displays anticoagulant activity via inhibition of factor XIa. Toxicon 2018;152:9-15. [PMID: 30012473 DOI: 10.1016/j.toxicon.2018.07.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
83 Berdiaki A, Neagu M, Giatagana EM, Kuskov A, Tsatsakis AM, Tzanakakis GN, Nikitovic D. Glycosaminoglycans: Carriers and Targets for Tailored Anti-Cancer Therapy. Biomolecules 2021;11:395. [PMID: 33800172 DOI: 10.3390/biom11030395] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
84 Kozlowski AM, Yates EA, Roubroeks JP, Tømmeraas K, Smith AM, Morris GA. Hydrolytic Degradation of Heparin in Acidic Environments: Nuclear Magnetic Resonance Reveals Details of Selective Desulfation. ACS Appl Mater Interfaces 2021;13:5551-63. [PMID: 33471995 DOI: 10.1021/acsami.0c20198] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
85 Kardeby C, Damaskinaki FN, Sun Y, Watson SP. Is the endogenous ligand for PEAR1 a proteoglycan: clues from the sea. Platelets 2021;32:779-85. [PMID: 33356751 DOI: 10.1080/09537104.2020.1863938] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
86 Hsiao FS, Yang SK, Lin JM, Chen YW, Chen CS. Protein interactome analysis of iduronic acid-containing glycosaminoglycans reveals a novel flagellar invasion factor MbhA. J Proteomics 2019;208:103485. [PMID: 31421271 DOI: 10.1016/j.jprot.2019.103485] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
87 Baytas SN, Linhardt RJ. Advances in the preparation and synthesis of heparin and related products. Drug Discov Today 2020;25:2095-109. [PMID: 32947045 DOI: 10.1016/j.drudis.2020.09.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
88 Thakuri A, Banerjee M, Chatterjee A. Sulfonate‐Functionalized AIEgens: Strategic Approaches Beyond Water Solubility for Sensing and Imaging Applications. ChemPhotoChem. [DOI: 10.1002/cptc.202100234] [Reference Citation Analysis]
89 Qiao M, Lin L, Xia K, Li J, Zhang X, Linhardt RJ. Recent advances in biotechnology for heparin and heparan sulfate analysis. Talanta 2020;219:121270. [PMID: 32887160 DOI: 10.1016/j.talanta.2020.121270] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
90 Ramirez GA, Manfredi AA, Rovere-Querini P, Maugeri N. Bet on NETs! Or on How to Translate Basic Science into Clinical Practice. Front Immunol 2016;7:417. [PMID: 27790216 DOI: 10.3389/fimmu.2016.00417] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
91 Cheng Q, He Y, Ge Y, Zhou J, Song G. Ultrasensitive detection of heparin by exploiting the silver nanoparticle-enhanced fluorescence of graphitic carbon nitride (g-C3N4) quantum dots. Mikrochim Acta 2018;185:332. [PMID: 29926199 DOI: 10.1007/s00604-018-2864-9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
92 Gonzalez-delgado P, Fernandez J. Hypersensitivity reactions to heparins. Current Opinion in Allergy & Clinical Immunology 2016;16:315-22. [DOI: 10.1097/aci.0000000000000281] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
93 Balogh G, Gyöngyösi T, Timári I, Herczeg M, Borbás A, Fehér K, Kövér KE. Comparison of Carbohydrate Force Fields Using Gaussian Accelerated Molecular Dynamics Simulations and Development of Force Field Parameters for Heparin-Analogue Pentasaccharides. J Chem Inf Model 2019;59:4855-67. [DOI: 10.1021/acs.jcim.9b00666] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
94 Sampaio TBP, Costa BB, Moreira TA, Cabral LM, Silva LCRP, Mourão PAS, Vilanova E, Cinelli LP. Insights on chemical-biological correlations learned from investigations on the sulfated galactan from the marine alga Bothryocladia occidentalis. Int J Biol Macromol 2020;158:471-6. [PMID: 32376249 DOI: 10.1016/j.ijbiomac.2020.04.085] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
95 Shah S, Karathanasi A, Revythis A, Ioannidou E, Boussios S. Cancer-Associated Thrombosis: A New Light on an Old Story. Diseases 2021;9:34. [PMID: 34064390 DOI: 10.3390/diseases9020034] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
96 Santos GR, Piquet AA, Glauser BF, Tovar AM, Pereira MS, Vilanova E, Mourão PA. Systematic Analysis of Pharmaceutical Preparations of Chondroitin Sulfate Combined with Glucosamine. Pharmaceuticals (Basel) 2017;10:E38. [PMID: 28368296 DOI: 10.3390/ph10020038] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
97 Ding L, Shu Z, Hao J, Luo X, Ye X, Zhu W, Duan W, Chen Z. Schixator, a new FXa inhibitor from Schistosoma japonicum with antithrombotic effect and low bleeding risk. Biochemical and Biophysical Research Communications 2022;603:138-43. [DOI: 10.1016/j.bbrc.2022.03.005] [Reference Citation Analysis]
98 Walkowiak JJ, Ballauff M, Zimmermann R, Freudenberg U, Werner C. Thermodynamic Analysis of the Interaction of Heparin with Lysozyme. Biomacromolecules 2020;21:4615-25. [DOI: 10.1021/acs.biomac.0c00780] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
99 Aslani S, Kabiri M, Hosseinzadeh S, Hanaee-ahvaz H, Taherzadeh ES, Soleimani M. The applications of heparin in vascular tissue engineering. Microvascular Research 2020;131:104027. [DOI: 10.1016/j.mvr.2020.104027] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 6.5] [Reference Citation Analysis]
100 Ding L, Hao J, Luo X, Chen Z. Engineering varied serine protease inhibitors by converting P1 site of BF9, a weakly active Kunitz-type animal toxin. Int J Biol Macromol 2018;120:1190-7. [PMID: 30172807 DOI: 10.1016/j.ijbiomac.2018.08.178] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
101 Bertini S, Risi G, Guerrini M, Carrick K, Szajek AY, Mulloy B. Molecular Weights of Bovine and Porcine Heparin Samples: Comparison of Chromatographic Methods and Results of a Collaborative Survey. Molecules 2017;22:E1214. [PMID: 28753946 DOI: 10.3390/molecules22071214] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
102 Kar S, Bankston P, Afosah DK, Al-Horani RA. Lignosulfonic Acid Sodium Is a Noncompetitive Inhibitor of Human Factor XIa. Pharmaceuticals (Basel) 2021;14:886. [PMID: 34577586 DOI: 10.3390/ph14090886] [Reference Citation Analysis]
103 Baytas SN, Varghese SS, Jin W, Yu Y, He P, Douaisi M, Zhang F, Brodfuehrer P, Xia K, Dordick JS, Linhardt RJ. Preparation of Low Molecular Weight Heparin from a Remodeled Bovine Intestinal Heparin. J Med Chem 2021;64:2242-53. [PMID: 33586962 DOI: 10.1021/acs.jmedchem.0c02019] [Reference Citation Analysis]
104 Qiu M, Huang S, Luo C, Wu Z, Liang B, Huang H, Ci Z, Zhang D, Han L, Lin J. Pharmacological and clinical application of heparin progress: An essential drug for modern medicine. Biomed Pharmacother 2021;139:111561. [PMID: 33848775 DOI: 10.1016/j.biopha.2021.111561] [Reference Citation Analysis]
105 Harenberg J, Favaloro E. COVID-19: progression of disease and intravascular coagulation - present status and future perspectives. Clin Chem Lab Med 2020;58:1029-36. [PMID: 32406381 DOI: 10.1515/cclm-2020-0502] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 20.0] [Reference Citation Analysis]
106 Achazi K, Haag R, Ballauff M, Dernedde J, Kizhakkedathu JN, Maysinger D, Multhaup G. Understanding the Interaction of Polyelectrolyte Architectures with Proteins and Biosystems. Angew Chem Int Ed Engl 2021;60:3882-904. [PMID: 32589355 DOI: 10.1002/anie.202006457] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
107 Wang TF, Billett HH, Connors JM, Soff GA. Approach to Cancer-Associated Thrombosis: Challenging Situations and Knowledge Gaps. Oncologist 2021;26:e17-23. [PMID: 33275323 DOI: 10.1002/onco.13570] [Reference Citation Analysis]
108 Rajarathnam K, Desai UR. Structural Insights Into How Proteoglycans Determine Chemokine-CXCR1/CXCR2 Interactions: Progress and Challenges. Front Immunol 2020;11:660. [PMID: 32391006 DOI: 10.3389/fimmu.2020.00660] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
109 Glauser BF, Santos GRC, Silva JD, Tovar AMF, Pereira MS, Vilanova E, Mourão PAS. Chemical and pharmacological aspects of neutralization of heparins from different animal sources by protamine. J Thromb Haemost 2018;16:1789-99. [DOI: 10.1111/jth.14221] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
110 Ho P, Ho C, Wong W. Recent advances of iridium(III) metallophosphors for health-related applications. Coordination Chemistry Reviews 2020;413:213267. [DOI: 10.1016/j.ccr.2020.213267] [Cited by in Crossref: 35] [Cited by in F6Publishing: 18] [Article Influence: 17.5] [Reference Citation Analysis]
111 Boothello RS, Sankaranarayanan NV, Afosah DK, Karuturi R, Al-Horani RA, Desai UR. Studies on fragment-based design of allosteric inhibitors of human factor XIa. Bioorg Med Chem 2020;28:115762. [PMID: 32992249 DOI: 10.1016/j.bmc.2020.115762] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
112 Ghiselli G. Heparin Binding Proteins as Therapeutic Target: An Historical Account and Current Trends. Medicines (Basel) 2019;6:E80. [PMID: 31362364 DOI: 10.3390/medicines6030080] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
113 Rasmuson J, Kenne E, Wahlgren M, Soehnlein O, Lindbom L. Heparinoid sevuparin inhibits Streptococcus-induced vascular leak through neutralizing neutrophil-derived proteins. FASEB J 2019;33:10443-52. [PMID: 31216421 DOI: 10.1096/fj.201900627R] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
114 Cazzola M, Matera MG. Editorial overview: Respiratory: Pulmonary pharmacology - It is time for a breath of fresh air. Curr Opin Pharmacol 2018;40:iv-viii. [PMID: 29859765 DOI: 10.1016/j.coph.2018.05.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
115 Fu L, Li K, Mori D, Hirakane M, Lin L, Grover N, Datta P, Yu Y, Zhao J, Zhang F, Yalcin M, Mousa SA, Dordick JS, Linhardt RJ. Enzymatic Generation of Highly Anticoagulant Bovine Intestinal Heparin. J Med Chem 2017;60:8673-9. [DOI: 10.1021/acs.jmedchem.7b01269] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
116 van Haren FMP, Page C, Laffey JG, Artigas A, Camprubi-Rimblas M, Nunes Q, Smith R, Shute J, Carroll M, Tree J, Carroll M, Singh D, Wilkinson T, Dixon B. Nebulised heparin as a treatment for COVID-19: scientific rationale and a call for randomised evidence. Crit Care 2020;24:454. [PMID: 32698853 DOI: 10.1186/s13054-020-03148-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 12.0] [Reference Citation Analysis]
117 Glass CA. Recombinant Heparin-New Opportunities. Front Med (Lausanne) 2018;5:341. [PMID: 30564580 DOI: 10.3389/fmed.2018.00341] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
118 Kalathottukaren MT, Haynes CA, Kizhakkedathu JN. Approaches to prevent bleeding associated with anticoagulants: current status and recent developments. Drug Deliv Transl Res 2018;8:928-44. [PMID: 28741113 DOI: 10.1007/s13346-017-0413-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
119 Yang S, Niu Q, Gan L, Zhang X, Tu L, Zuo L. Effect of long-term use of unfractionated or low-molecular-weight heparin on bone mineral density in maintenance hemodialysis patients. Hemodial Int 2020;24:374-82. [PMID: 32520445 DOI: 10.1111/hdi.12854] [Reference Citation Analysis]
120 Shute JK, Calzetta L, Cardaci V, di Toro S, Page CP, Cazzola M. Inhaled nebulised unfractionated heparin improves lung function in moderate to very severe COPD: A pilot study. Pulm Pharmacol Ther 2018;48:88-96. [PMID: 28986203 DOI: 10.1016/j.pupt.2017.10.001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
121 Maffei FHA. Future prospects for prophylactic and therapeutic management of venous thrombosis: antithrombotic substances with lower risk of hemorrhage? J Vasc Bras 2019;18:e20190036. [PMID: 31320885 DOI: 10.1590/1677-5449.190036] [Reference Citation Analysis]
122 Afratis NA, Karamanou K, Piperigkou Z, Vynios DH, Theocharis AD. The role of heparins and nano-heparins as therapeutic tool in breast cancer. Glycoconj J 2017;34:299-307. [PMID: 27778131 DOI: 10.1007/s10719-016-9742-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
123 Pan Q, Zhang C, Wu X, Chen Y. Identification of a heparosan heptasaccharide as an effective anti-inflammatory agent by partial desulfation of low molecular weight heparin. Carbohydr Polym 2020;227:115312. [PMID: 31590876 DOI: 10.1016/j.carbpol.2019.115312] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
124 Mohamed S, Coombe DR. Heparin Mimetics: Their Therapeutic Potential. Pharmaceuticals (Basel) 2017;10:E78. [PMID: 28974047 DOI: 10.3390/ph10040078] [Cited by in Crossref: 45] [Cited by in F6Publishing: 36] [Article Influence: 9.0] [Reference Citation Analysis]
125 Eliassen E, Marci R, Di Luca D, Rizzo R. The use of heparin in infertility and recurrent pregnancy loss: Are its antiviral properties at play? Medical Hypotheses 2017;102:41-7. [DOI: 10.1016/j.mehy.2017.03.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
126 Shi D, Beasock D, Fessler A, Szebeni J, Ljubimova JY, Afonin KA, Dobrovolskaia MA. To PEGylate or not to PEGylate: Immunological properties of nanomedicine's most popular component, polyethylene glycol and its alternatives. Adv Drug Deliv Rev 2021;180:114079. [PMID: 34902516 DOI: 10.1016/j.addr.2021.114079] [Reference Citation Analysis]
127 Niu Q, Yang S, Gan L, Zhao H, Zuo L. Different type and dosage of heparin were not associated with the progression of coronary artery calcification in haemodialysis patients. Nephrology (Carlton) 2020;25:551-8. [PMID: 31339604 DOI: 10.1111/nep.13632] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
128 Yu Y, Fu L, He P, Xia K, Varghese S, Wang H, Zhang F, Dordick J, Linhardt RJ. Chemobiocatalytic Synthesis of a Low-Molecular-Weight Heparin. ACS Chem Biol 2022. [PMID: 35201757 DOI: 10.1021/acschembio.1c00928] [Reference Citation Analysis]
129 Wang X, Jiang C, Qin Y, Peng Y, Wen G, Liang A, Jiang Z. SERS spectral study of HAuCl4-cysteine nanocatalytic reaction and its application for detection of heparin sodium with label-free VB4r molecular probe. Sci Rep 2017;7:45979. [PMID: 28378828 DOI: 10.1038/srep45979] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
130 Fonseca RJC, Mourão PAS. Pharmacological Activities of Sulfated Fucose-Rich Polysaccharides after Oral Administration: Perspectives for the Development of New Carbohydrate-Based Drugs. Mar Drugs 2021;19:425. [PMID: 34436263 DOI: 10.3390/md19080425] [Reference Citation Analysis]
131 Afosah DK, Al-Horani RA. Sulfated Non-Saccharide Glycosaminoglycan Mimetics as Novel Drug Discovery Platform for Various Pathologies. Curr Med Chem 2020;27:3412-47. [PMID: 30457046 DOI: 10.2174/0929867325666181120101147] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
132 Manfredi AA, Rovere-Querini P, D'Angelo A, Maugeri N. Low molecular weight heparins prevent the induction of autophagy of activated neutrophils and the formation of neutrophil extracellular traps. Pharmacol Res 2017;123:146-56. [PMID: 28161237 DOI: 10.1016/j.phrs.2016.08.008] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 7.8] [Reference Citation Analysis]
133 Al-Horani RA, Afosah DK. Recent advances in the discovery and development of factor XI/XIa inhibitors. Med Res Rev 2018;38:1974-2023. [PMID: 29727017 DOI: 10.1002/med.21503] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
134 Drouet L, Harenberg J, Torri G. The Multiple Faces of Heparin: Opportunities in COVID-19 Infection and Beyond. Thromb Haemost 2020;120:1347-50. [PMID: 32920810 DOI: 10.1055/s-0040-1716543] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
135 Liu Y, Mu S, Li X, Liang Y, Wang L, Ma X. Unfractionated Heparin Alleviates Sepsis-Induced Acute Lung Injury by Protecting Tight Junctions. Journal of Surgical Research 2019;238:175-85. [DOI: 10.1016/j.jss.2019.01.020] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 10.0] [Reference Citation Analysis]
136 Merrill JT, Erkan D, Winakur J, James JA. Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications. Nat Rev Rheumatol 2020;16:581-9. [PMID: 32733003 DOI: 10.1038/s41584-020-0474-5] [Cited by in Crossref: 81] [Cited by in F6Publishing: 70] [Article Influence: 40.5] [Reference Citation Analysis]
137 Koffas MA, Linhardt RJ, Thacker BE, Sharfstein ST. Metabolic engineering of mammalian cells to produce heparan sulfates. Emerging Topics in Life Sciences 2018;2:443-52. [DOI: 10.1042/etls20180007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
138 Shute JK, Puxeddu E, Calzetta L. Therapeutic use of heparin and derivatives beyond anticoagulation in patients with bronchial asthma or COPD. Curr Opin Pharmacol 2018;40:39-45. [PMID: 29455115 DOI: 10.1016/j.coph.2018.01.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
139 Neville K. The Basics of Antithrombotic Medications: How Do They Work and Why Should We Care? Topics in Geriatric Rehabilitation 2019;35:55-71. [DOI: 10.1097/tgr.0000000000000216] [Reference Citation Analysis]
140 Aláez-Versón CR, Lantero E, Fernàndez-Busquets X. Heparin: new life for an old drug. Nanomedicine (Lond) 2017;12:1727-44. [PMID: 28635544 DOI: 10.2217/nnm-2017-0127] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.6] [Reference Citation Analysis]
141 Nagarajan B, Sankaranarayanan NV, Desai UR. Rigorous analysis of free solution glycosaminoglycan dynamics using simple, new tools. Glycobiology 2020;30:516-27. [PMID: 32080710 DOI: 10.1093/glycob/cwaa015] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
142 Pérez del Río E, Santos F, Rodriguez Rodriguez X, Martínez-miguel M, Roca-pinilla R, Arís A, Garcia-fruitós E, Veciana J, Spatz JP, Ratera I, Guasch J. CCL21-loaded 3D hydrogels for T cell expansion and differentiation. Biomaterials 2020;259:120313. [DOI: 10.1016/j.biomaterials.2020.120313] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
143 Hui X, Geng X, Jia L, Xu Z, Ye L, Gu Y, Zhang AY, Feng ZG. Preparation and in vivo evaluation of surface heparinized small diameter tissue engineered vascular scaffolds of poly(ε-caprolactone) embedded with collagen suture. J Biomater Appl 2020;34:812-26. [PMID: 31475873 DOI: 10.1177/0885328219873174] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
144 Matera MG, Page C, Rogliani P, Calzetta L, Cazzola M. Therapeutic Monoclonal Antibodies for the Treatment of Chronic Obstructive Pulmonary Disease. Drugs 2016;76:1257-70. [DOI: 10.1007/s40265-016-0625-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 4.3] [Reference Citation Analysis]
145 Wheeler AP, Gailani D. The Intrinsic Pathway of Coagulation as a Target for Antithrombotic Therapy. Hematol Oncol Clin North Am 2016;30:1099-114. [PMID: 27637310 DOI: 10.1016/j.hoc.2016.05.007] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 5.4] [Reference Citation Analysis]
146 Zhao C, Li S, Zhang J, Huang Y, Zhang L, Zhao F, Du X, Hou J, Zhang T, Shi C, Wang P, Huo R, Woodman OL, Qin CX, Xu H, Huang L. Current state and future perspective of cardiovascular medicines derived from natural products. Pharmacol Ther 2020;216:107698. [PMID: 33039419 DOI: 10.1016/j.pharmthera.2020.107698] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
147 Jeske W, Kouta A, Farooqui A, Siddiqui F, Rangnekar V, Niverthi M, Laddu R, Hoppensteadt D, Iqbal O, Walenga J, Fareed J. Bovine Mucosal Heparins Are Comparable to Porcine Mucosal Heparin at USP Potency Adjusted Levels. Front Med (Lausanne) 2018;5:360. [PMID: 30687709 DOI: 10.3389/fmed.2018.00360] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
148 Chen N, Zhang H, Zong X, Li S, Wang J, Wang Y, Jin M. Polysaccharides from Auricularia auricula: Preparation, structural features and biological activities. Carbohydrate Polymers 2020;247:116750. [DOI: 10.1016/j.carbpol.2020.116750] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
149 Lin YC, Ko YC, Hung SC, Lin YT, Lee JH, Tsai JY, Kung PH, Tsai MC, Chen YF, Wu CC. Selective Inhibition of PAR4 (Protease-Activated Receptor 4)-Mediated Platelet Activation by a Synthetic Nonanticoagulant Heparin Analog. Arterioscler Thromb Vasc Biol 2019;39:694-703. [PMID: 30727756 DOI: 10.1161/ATVBAHA.118.311758] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]